Skip to content

Effect of parenteral caffeine citrate for prevention of apnea in very preterm neonates in NICU ward

The survey of the effect of parenteral caffeine citrate for prevention of apnea in very preterm neonates in NICU part of Shahid-Motahary hospital for one year

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017102637023N1
Enrollment
100
Registered
2017-11-14
Start date
2017-01-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnoea. Primary sleep apnoea of newborn

Interventions

Intervention 1: Control received no caffeine. Intervention 2: Infants of intervention group on the second day of birth (24-48 h) intravenous caffeine citrate with a dose of 20mg/kg and then the mainte
Placebo
Treatment - Drugs
Control received no caffeine.
Infants of intervention group on the second day of birth (24-48 h) intravenous caffeine citrate with a dose of 20mg/kg and then the maintenance dose 24 hours after the first injection with a dose of 5

Sponsors

Urmia University of Mecidal Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 8 Months

Inclusion criteria

Inclusion criteria: Inclusion criteria for entering were the premature newborns weighing less than 1500 grams at least 24 hours of age and having self-contained breathing in the first 24 hours of life; and exclusion criteria were maternal major anomalies, the incidence of apnea in the first 24 hours of life and the need for mechanical ventilation in 24 The first hour of birth, cyanotic heart disease, small age for gestational age (SGA, IUGR), intrauterine growth retardation, as well as clinical evidence for sepsis during the first 7 days of birth and IVH grade 3 or 4 during the first week of life.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Apnoea. Timepoint: From beginning to end of intervention. Method of measurement: The number of cases of apnea reported by the nurse.

Secondary

MeasureTime frame
Bradicardia. Timepoint: From beginning to end of intervention. Method of measurement: The number of cases of bradicardia reported by the nurse.;Cyanosis. Timepoint: From beginning to end of intervention. Method of measurement: The number of cases of cyanosis reported by the nurse.;Duration of oxygen demand. Timepoint: From beginning to end of intervention. Method of measurement: Duration of oxygen demand reported by the nurse.;Duration of NCPAP demand. Timepoint: From beginning to end of intervention. Method of measurement: Duration of NCPAP demand reported by the nurse.;Duration of mechanical ventilation demand. Timepoint: From beginning to end of intervention. Method of measurement: Duration of mechanical ventilation demand reported by the nurse.;Hospitalization. Timepoint: From beginning to end of intervention. Method of measurement: Patients' Records.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Zahra Fakoor

Urmia University of Medical Sciences

drfakoor@umsu.ac.ir+98 44 3224 4830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026